摘要
背景与目的顺铂(DDP)与长春瑞滨(NVB)联合应用是当前公认的治疗非小细胞肺癌(NSCLC)的标准化疗方案之一。但顺铂所致的恶心呕吐等消化道症状严重影响患者的生活质量。本研究拟观察奥沙利铂(OXA)和顺铂分别与长春瑞滨联合治疗晚期NSCLC的临床疗效和不良反应。方法168例中晚期NSCLC患者随机进入奥沙利铂(NO)组和顺铂(NP)组。结果NO组与NP组总有效率分别为38.6%和40.0%,1年生存率分别为33.7%和31.8%,两组间差异均无统计学意义(P>0.05)。两组的主要不良反应为骨髓抑制、恶心呕吐及周围神经炎。NO组的白细胞减少及恶心呕吐发生率显著低于NP组(P<0.05);其周围神经毒性的发生率明显高于NP组(P<0.001),但两组间Ⅲ+Ⅳ度周围神经炎发生率差异无统计学意义(P>0.05)。两组间肝肾功损害、脱发和静脉炎发生率差异无统计学意义。结论两种方案在晚期NSCLC治疗中疗效和1年生存率相近,但NO组除周围神经毒性发生率较高外,其它毒性较NP组更轻,患者更易耐受。
Background and objective Cisplatin plus navelbine （NO） is a standard combination chemotherapy regimen for non small cell lung cancer （NSCLC）, but severe toxicities due to cisplatin often influence the quality of life in the patients, such as nausea and vomiting. The aims of this study are to evaluate the effi cacy and toxicity of combined chemotherapy of oxaliplatin and cisplatin plus navelbine in treatment of advanced NSCLC. Methods A total of 168 patients were randomly divided into NO group （n=83） and NP group （n= 85）. Results The overall response rate was 38.6% in NO group and 40.0% in NP group respectively. 1-year survival rate was 33.7% in NO group and 31.8% in NP group. There was no significant difference in response rate and 1-year survival between the two groups （P〈0.05）. The major side effects were myelosuppression, nausea/vomiting and neurotoxicity in the two groups. Incidences of leukopenia and nausea/vomiting were significantly lower in NO group than those in NP group （P〈0.05）, but neurotoxicity in NO group was more obvious than that in NP group （P〈0. 001）. Conclusion The efficacy and 1 year survival of combined chemo therapy of oxaliplatin and cisplatin plus navelbine are similar in the treatment of advanced NSCLC. However, the side effects of oxaliplatin plus navelbine are lower except for neurotoxicity.
出处
《中国肺癌杂志》
CAS
2005年第6期538-541,共4页
Chinese Journal of Lung Cancer
关键词
奥沙利铂
顺铂
长春瑞滨
化疗
非小细胞肺癌
Oxaliplatin Cisplatin Navelbine Chemotherapy Non-small cell lung cancer
